Press Release: SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026

Dow Jones

02/03

SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE $(SIBN)$ is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 200 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE$(R)$ is a registered trademark of SI-BONE, Inc. (c)2026 SI-BONE, Inc. All Rights Reserved.

Marnelli.delcastillo@si-bone.com

650-271-7515

(END) Dow Jones Newswires

February 02, 2026 16:30 ET (21:30 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2608818547"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2608818547\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2608818547?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 05:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608818547","market":"fut","top_or_hot":-1,"title":"Press Release: SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. \n</p>\n<p>\n     Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the \"Investors\" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event. \n</p>\n<p>\n     About SI-BONE, Inc. \n</p>\n<p>\n     SI-BONE <a href=\"https://laohu8.com/S/SIBN\">$(SIBN)$</a> is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 200 peer reviewed publications. \n</p>\n<p>\n     For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com. \n</p>\n<p>\n     SI-BONE<a href=\"https://laohu8.com/S/R\">$(R)$</a> is a registered trademark of SI-BONE, Inc. (c)2026 SI-BONE, Inc. All Rights Reserved. \n</p>\n<p>\n     Marnelli.delcastillo@si-bone.com \n</p>\n<p>\n     650-271-7515 \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2026 16:30 ET (21:30 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-02-03 05:30</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. \n</p>\n<p>\n     Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the \"Investors\" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event. \n</p>\n<p>\n     About SI-BONE, Inc. \n</p>\n<p>\n     SI-BONE <a href=\"https://laohu8.com/S/SIBN\">$(SIBN)$</a> is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 200 peer reviewed publications. \n</p>\n<p>\n     For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com. \n</p>\n<p>\n     SI-BONE<a href=\"https://laohu8.com/S/R\">$(R)$</a> is a registered trademark of SI-BONE, Inc. (c)2026 SI-BONE, Inc. All Rights Reserved. \n</p>\n<p>\n     Marnelli.delcastillo@si-bone.com \n</p>\n<p>\n     650-271-7515 \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2026 16:30 ET (21:30 GMT)\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SI","symbol_name":"Shoulder Innovations, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2608818547","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608818547","pubTimestamp":1770067800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"SANTA CLARA, Calif., Feb. 02, 2026  -- SI-BONE, Inc. , the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.SI-BONE  is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 200 peer reviewed publications.F","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SI":"Shoulder Innovations, Inc.","SIBN":"SI-BONE, Inc.","BK4082":"医疗保健设备","BK4232":"货物陆运","BK4211":"区域性银行","BK4022":"陆运","R":"瑞德系统"},"translate_title":"新闻稿：SI-BONE将于2026年2月23日公布2025年第四季度和全年财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"R":1,"SIBN":1,"SI":1.5},"content_text":"SANTA CLARA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the fourth quarter and full year ended December 31, 2025 after market close on Monday, February 23, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. \n\n\n     Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/zfxy6yox. Live audio of the webcast will be available on the \"Investors\" section of the company's website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event. \n\n\n     About SI-BONE, Inc. \n\n\n     SI-BONE $(SIBN)$ is the global leader in developing procedural solutions to address clinical challenges associated with compromised bone. SI-BONE's expertise in additive manufacturing has resulted in a technology platform with market-leading applications in SI joint fusion, adult spinal deformity and pelvic trauma. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 200 peer reviewed publications. \n\n\n     For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com. \n\n\n     SI-BONE$(R)$ is a registered trademark of SI-BONE, Inc. (c)2026 SI-BONE, Inc. All Rights Reserved. \n\n\n     Marnelli.delcastillo@si-bone.com \n\n\n     650-271-7515 \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 16:30 ET (21:30 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}